The Impact of the PAI-1 A(-844)G Promoter Polymorphism on the Risk and Extent of Coronary Heart Disease

• References

• 1 Hamsten A, de Faire U, Waldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 02: 3-9.
• 2 Cortellaro M, Cofrancesco E, Boscheti C. Increased fibrin turnover and high PAI-I activity as predictors of ischemic events in atherosclerotic patients: a case control study. Arterioscler Thromb 1993; 13: 1412-17.
• 3 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 4 Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Huhan-Vague I. Five frequent polymorphisms of the PAI-1 gene. Arterioscler Tromb Vasc Biol 1997; 17: 851-8.
• 5 Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G/5G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with the risk and extent of coronary artery disease. Thromb Haemost 1999; 82: 1121-6.
• 6 Morange PE, Henry M, Tregouet D, Granel B, Aillaud MF, Alessi MC, Juhan-Vague AI. The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 2000; 20: 1871-91.
• 7 Gardemann A, Lohre J, Katz N, Tillmanns H, Haberbosch W. The T allele of the missense Glu298Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis 2002; 60: 167-75.
• 8 Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.